Sotac Pharmaceuticals Ltd

Sotac Pharmaceuticals has a debt-to-equity ratio of 0.82, indicating a moderate reliance on debt financing, and a current ratio of 1.35, suggesting it has sufficient short-term assets to cover its short-term liabilities. However, the company's liquidity position is rated as medium, and its operating cash flow is negative at -43.31 million INR, which raises concerns about its ability to fund operations without external financing. The company's free cash flow is also negative at -39.06 million INR, further highlighting its cash flow challenges. In terms of profitability, Sotac Pharmaceuticals reports a return on equity (ROE) of 15.07% and a return on assets (ROA) of 6.46%, which are key metrics for evaluating the efficiency of equity and asset utilization. These figures are to be compared against the industry's preferred metrics, which typically emphasize ROE and ROA as indicators of financial performance. The company's operating income of 98.14 million INR and net income of 80.27 million INR reflect its profitability, but the negative operating and free cash flows suggest operational inefficiencies or high capital expenditures. The company's revenue is distributed across a range of therapeutic areas and geographic markets, with products supplied across 14 states in India and exported to over 20 countries. However, the input data does not provide specific revenue concentration figures for individual segments or regions, so it is unclear whether the company is heavily reliant on any particular market or product line. Looking at the company's growth trajectory, the input data does not provide specific outlook figures for the current or next fiscal year. However, the company's capital expenditures of -170.16 million INR indicate significant investment in infrastructure or expansion, which could signal a growth-oriented strategy. The negative operating and free cash flows, however, suggest that the company may be facing financial constraints that could impact its ability to sustain growth. The risk assessment for Sotac Pharmaceuticals highlights a medium liquidity risk and a low dilution risk. The company's net cash position is negative after subtracting total debt, which could limit its ability to meet short-term obligations without additional financing. The low dilution risk suggests that the company is not expected to issue a large number of new shares in the near term, which is a positive sign for existing shareholders. Recent events and filings for Sotac Pharmaceuticals are not detailed in the input data, so it is unclear whether there have been any significant developments that could impact the company's financial position or strategic direction. The absence of specific information on recent events means that the company's current situation must be assessed based on the available financial data.